Fundació Privada Institut D'Investigació Oncològica De Vall Hebron;Astrazeneca UK Limited;Xentech SAS
发明人:
Violeta SERRA ELIZALDE,Judith BALMAÑA GELPI,Cristina CRUZ ZAMBRANO,Alba LLOP GUEVARA,Marta CASTROVIEJO BERMEJO,Mark J. O?CONNOR,Gemma Nicole JONES
申请号：
US16956112
公开号：
US20200319182A1
申请日:
2018.12.21
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The invention provides a method allowing to determine whether a subject diagnosed with cancer is sensitive or resistant to an anti-cancer treatment, based on the level of cells with RAD51 foci in a sample containing tumor cells isolated from said subject, wherein the subject has not received at 24 hours prior to the isolation of the sample, a chemotherapy selected from the group consisting of AC, FEC, ECF and navelbine/epirubicin, and wherein the sample has not been treated with a method that induces DNA damage before determining the level of cells with RAD51 foci.
